Physician profile
Michael Chesner
NPI 1154355766
$4,829.14
in general payments reported to CMS, 2019-2025
46 companies · $517 in 2025
The $517 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,257 · 2020: $454 · 2021: $410 · 2022: $917 · 2023: $777 · 2024: $498 · 2025: $517.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,691 · Education: $99.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,690.70 |
| Education | $99.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic Vascular, INC. | $981.62 | 2019-2020 | |
| Astrazeneca Pharmaceuticals Lp | $548.63 | 2020-2025 | Farxiga, Brilinta, Wainua |
| Merck Sharp & Dohme LLC | $419.05 | 2021-2025 | Verquvo, Belsomra, Zerbaxa |
| Novartis Pharmaceuticals Corporation | $376.56 | 2019-2025 | |
| Medtronic, INC. | $297.08 | 2021-2024 | Venaseal |
| Amarin Pharma, INC. | $228.94 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $198.96 | 2019-2022 | |
| Esperion Therapeutics, INC. | $140.31 | 2020-2024 | Nexletol |
| Paratek Pharmaceuticals, INC. | $127.09 | 2022-2025 | Nuzyra |
| Pfizer INC. | $101.74 | 2019-2025 | |
| Impulse Dynamics (USA) INC. | $96.87 | 2022 | |
| Exact Sciences Corporation | $95.06 | 2024-2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Boehringer Ingelheim Pharmaceuticals, INC. | $87.05 | 2021-2024 | Jardiance |
| Boston Scientific Corporation | $80.91 | 2023-2025 | Watchman Flx |
| Philips North America LLC | $79.80 | 2025 | Extended Holter, Ecc Solutions |
Show all 46 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alexion Pharmaceuticals, INC. | $77.75 | 2024 | Ultomiris |
| E.R. Squibb & Sons, L.L.C. | $64.79 | 2022-2023 | Eliquis, Camzyos |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $58.39 | 2023 | Lifevest |
| Calliditas Therapeutics US INC. | $58.35 | 2023-2024 | Tarpeyo |
| Genentech USA, INC. | $55.10 | 2019-2021 | |
| Bardy Diagnostics, INC. | $53.00 | 2021 | |
| Edwards Lifesciences Corporation | $50.85 | 2019-2023 | Sapien 3 Ultra Resilia |
| Eisai INC. | $46.81 | 2021-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $35.87 | 2022-2024 | |
| Ucb, INC. | $34.07 | 2025 | Rystiggo |
| Biotronik INC. | $32.55 | 2020 | |
| Scpharmaceuticals INC. | $30.27 | 2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $29.39 | 2024 | Hyqvia |
| Teva Pharmaceuticals USA, INC. | $26.98 | 2025 | Ajovy |
| Kowa Pharmaceuticals America, INC. | $26.97 | 2020-2022 | |
| Gilead Sciences, INC. | $21.93 | 2022 | |
| Cvrx, INC. | $21.49 | 2025 | Barostim Neo System |
| Janssen Biotech, INC. | $20.77 | 2025 | |
| Alnylam Pharmaceuticals INC. | $20.46 | 2023 | Givlaari |
| Baxter Healthcare | $20.06 | 2023 | Hillrom - Carnation Ambulatory Monitor |
| Ethicon US, LLC | $19.43 | 2024 | Dermabond, Stratafix |
| Tanabe Pharma America, INC. | $18.84 | 2025 | Radicava |
| Amgen INC. | $18.40 | 2022 | |
| Impel Pharmaceuticals LLC | $18.09 | 2025 | Trudhesa |
| Novo Nordisk INC | $17.55 | 2021 | |
| Pacira Pharmaceuticals Incorporated | $15.83 | 2022 | |
| Ultragenyx Pharmaceutical INC. | $15.71 | 2020 | |
| Ge Healthcare | $15.44 | 2022 | |
| Novavax INC | $15.16 | 2023 | Novavax Covid-19 Vaccine, Adjuvanted |
| Abbott Laboratories | $14.95 | 2024 | Freestyle Libre 3 |
| Aurinia Pharma U.S., INC. | $14.22 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Chesner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.